{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:12:49Z","timestamp":1790957569836,"version":"4.1.0"},"reference-count":25,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2021.42078","type":"journal-article","created":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T11:01:06Z","timestamp":1641380466000},"page":"e2142078","source":"Crossref","is-referenced-by-count":81,"title":["Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Patients With Type 2 Diabetes and Other Risk Factors for Cardiovascular Disease"],"prefix":"10.1001","volume":"5","author":[{"given":"Mukul","family":"Bhattarai","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Southern Illinois University School of Medicine, Springfield"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsin","family":"Salih","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Southern Illinois University School of Medicine, Springfield"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjari","family":"Regmi","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Southern Illinois University School of Medicine, Springfield"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Al-Akchar","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Southern Illinois University School of Medicine, Springfield"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhika","family":"Deshpande","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Southern Illinois University School of Medicine, Springfield"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zurain","family":"Niaz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Southern Illinois University School of Medicine, Springfield"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Kulkarni","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Southern Illinois University School of Medicine, Springfield"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momin","family":"Siddique","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Southern Illinois University School of Medicine, Springfield"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Hegde","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Southern Illinois University School of Medicine, Springfield"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,1,5]]},"reference":[{"issue":"4","key":"zoi211172r2","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-004619","article-title":"The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials.","volume":"4","author":"Sun","year":"2014","journal-title":"BMJ Open"},{"issue":"24","key":"zoi211172r3","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi211172r4","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease.","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"zoi211172r5","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes.","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"22","key":"zoi211172r6","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi211172r7","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes.","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"zoi211172r8","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes.","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi211172r9","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure.","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"issue":"21","key":"zoi211172r10","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction.","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"zoi211172r11","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease.","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"15","key":"zoi211172r12","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure.","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"zoi211172r13","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1002\/ehf2.v7.6","article-title":"Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis.","volume":"7","author":"Butler","year":"2020","journal-title":"ESC Heart Fail"},{"issue":"1","key":"zoi211172r14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/ejhf.v23.1","article-title":"SOLOIST-WHF and updated meta-analysis: sodium-glucose co-transporter 2 inhibitors should be initiated in patients hospitalized with worsening heart failure.","volume":"23","author":"Docherty","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"10166","key":"zoi211172r15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"issue":"21","key":"zoi211172r16","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","article-title":"Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial.","volume":"140","author":"Verma","year":"2019","journal-title":"Circulation"},{"issue":"23","key":"zoi211172r17","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1016\/j.jacc.2018.03.009","article-title":"Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 Study.","volume":"71","author":"Kosiborod","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"zoi211172r18","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1161\/CIRCULATIONAHA.117.031227","article-title":"Cardiovascular outcomes and risks after initiation of a sodium glucose cotransporter 2 inhibitor: results from the EASEL population-based cohort study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World).","volume":"137","author":"Udell","year":"2018","journal-title":"Circulation"},{"issue":"2","key":"zoi211172r19","article-title":"Cardiovascular risks associated with gender and aging.","volume":"6","author":"Rodgers","year":"2019","journal-title":"J Cardiovasc Dev Dis"},{"key":"zoi211172r20","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2147\/IJGM","article-title":"Determining 30-day readmission risk for heart failure patients: the Readmission After Heart Failure scale.","volume":"11","author":"Chamberlain","year":"2018","journal-title":"Int J Gen Med"},{"issue":"3","key":"zoi211172r21","doi-asserted-by":"publisher","first-page":"209","DOI":"10.7861\/fhj.2018-0039","article-title":"Predictors of 30-day hospital readmission: the direct comparison of number of discharge medications to the HOSPITAL score and LACE index.","volume":"6","author":"Robinson","year":"2019","journal-title":"Future Healthc J"},{"key":"zoi211172r22","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2147\/RMHP","article-title":"Economic burden of hospitalizations of Medicare beneficiaries with heart failure.","volume":"10","author":"Kilgore","year":"2017","journal-title":"Risk Manag Healthc Policy"},{"key":"zoi211172r23","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3389\/fcvm.2019.00186","article-title":"SGLT2 inhibitors play a salutary role in heart failure via modulation of the mitochondrial function.","volume":"6","author":"Maejima","year":"2020","journal-title":"Front Cardiovasc Med"},{"issue":"13","key":"zoi211172r24","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20133289","article-title":"Inhibition of sodium glucose cotransporters improves cardiac performance.","volume":"20","author":"Garc\u00eda-Ropero","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"2","key":"zoi211172r25","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/XCE.0000000000000229","article-title":"Comprehensive evaluation of cardiovascular efficacy and safety outcomes of SGLT2 inhibitors in high risk patients of cardiovascular disease: systematic review and meta-analysis.","volume":"10","author":"Bhattarai","year":"2020","journal-title":"Cardiovasc Endocrinol Metab"},{"key":"zoi211172r1","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases. Story of discovery: SGLT2 inhibitors: harnessing the kidneys to help treat diabetes. June 9, 2016. Accessed May 18, 2021. https:\/\/www.niddk.nih.gov\/news\/archive\/2016\/story-discovery-sglt2-inhibitors-harnessing-kidneys-help-treat-diabetes"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2787632\/bhattarai_2022_oi_211172_1640186079.15769.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T11:01:11Z","timestamp":1641380471000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2787632"}},"subtitle":["A Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2022,1,5]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,4]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.42078","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,5]]}}}